IMM-2902 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMM-2902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMM-2902 is under development for the treatment of solid tumors including HER2 positive breast cancer, stomach cancer, lung cancer, adenocarcinoma of the gastroesophageal junction, ovarian cancer, metastatic breast cancer, gastric cancer, cholangiocarcinoma, cervical cancer, cholangiocarcinoma, colon cancer, esophageal cancer, gastroesophageal junction carcinomas, colorectal cancer and non-small cell lung cancer . It is a bi-specific monoclonal antibody that acts by targeting CD47 and cells expressing tyrosine protein kinase ERBB 2 (HER2). It is administered through intravenous drip.
ImmuneOnco Biopharmaceuticals (Shanghai) overview
ImmuneOnco Biopharmaceuticals (Shanghai) is an early stage biopharmaceutical company, engaged in the production and commercialization of innovative cancer immunotherapy products with the aim of reversing cancer cell-induced immune inhibition and actively eradicating cancer cells. The company is headquartered in Shanghai, China.
For a complete picture of IMM-2902’s drug-specific PTSR and LoA scores, buy the report here.